Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call Transcript

Each one of those scaled for 700 products a year. And we’re obviously going to be launching out of the first clean room. So that gives us an immediate 700 capacity. And that also will bring online the second and the third clean room because it doesn’t make sense to operate clean rooms that are not being utilized from a capacity perspective yet. But the facility is fully built and obviously validated. But in terms of the actual ramp and how you run that is that you make sure that you have the right level of capacity at the right point in time. But the important thing is here is we have no limitation to actually ramp ahead of demand here. And I think that sets us apart from all the other launches that we’ve seen over the last few years.

Simon Baker: All right, thanks so much.

Christian Itin: Thank you, Simon.

Operator: This concludes our question-and-answer session. I would now like to turn it back to Christian Itin for closing remarks.

Christian Itin: Well, first of all, thanks all for joining. Looking forward, obviously, to seeing you at ASH with the additional data updates. And for those of you who happen to be in London middle of November, we’re looking to – or having a visit at the actual manufacturing facility. So if either on the analyst or investor side, there is interest, do visit the facility, please contact Susan Noonan, to join us for that visit. But you might find it interesting and helpful to sort of understand what the reality looks like on the CAR T therapy side and what you need to have in place to be able to launch. So with that, I’d like to thank you all for joining. I appreciate your time and speak to you soon. Thank you.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.